Research and Markets: Global Royalty Financing Deals in Pharma, Biotech and Diagnostics 2010-2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/7pr9fs/global_royalty) has announced the addition of the "Global Royalty Financing Deals in Pharma, Biotech and Diagnostics 2010-2015" report to their offering.

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2005 to early 2015.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2005 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - An overview of pharma and biotech royalty rates

Chapter 3 - Average royalty rates for pharma and biotech partnering

Chapter 4 - The royalty clause in pharma and biotech deals

Chapter 5 - Companies actively disclosing royalty rates

Chapter 6 - Royalty rate contract directory

For more information visit http://www.researchandmarkets.com/research/7pr9fs/global_royalty

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices